Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients

  • Authors:
    • Hiroshi Urakawa
    • Satoshi Tsukushi
    • Hideshi Sugiura
    • Kenji Yamada
    • Yoshihisa Yamada
    • Eiji Kozawa
    • Eisuke Arai
    • Naohisa Futamura
    • Naoki Ishiguro
    • Yoshihiro Nishida
  • View Affiliations

  • Published online on: September 26, 2014     https://doi.org/10.3892/ol.2014.2567
  • Pages: 2485-2488
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study investigated the safety and efficacy of neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcoma in adult and older patients. A total of 18 consecutive patients with bone sarcoma (American Joint Committee on Cancer stage II in 14 patients and stage IV in four) treated with neoadjuvant and adjuvant chemotherapy at Nagoya Musculoskeletal Oncology Group hospitals in Japan between 2004 and 2011 were reviewed. The treatment efficacy and side‑effects were evaluated. The responses to neoadjuvant chemotherapy were stable disease in 11 patients and progressive disease in three. Among the 12 evaluable patients, there were five with ≥90% tumor necrosis. The estimated overall survival (OS) rate at five years for the patients without metastasis prior to treatment was 56%. Major grade 3 or 4 side-effects included leukopenia in 14 cases, anemia in seven, thrombocytopenia in three, nausea in two and febrile neutropenia in two. One patient discontinued chemotherapy due to a temporarily depressed level of consciousness with arrhythmia (grade 2). The estimated five‑year OS rate in this study was acceptable in patients without metastasis prior to treatment. A better coordinated prospective study of this combination regimen for older patients with bone sarcoma will be required to clarify its efficacy and tolerability.
View Figures
View References

Related Articles

Journal Cover

December-2014
Volume 8 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Urakawa H, Tsukushi S, Sugiura H, Yamada K, Yamada Y, Kozawa E, Arai E, Futamura N, Ishiguro N, Nishida Y, Nishida Y, et al: Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients. Oncol Lett 8: 2485-2488, 2014
APA
Urakawa, H., Tsukushi, S., Sugiura, H., Yamada, K., Yamada, Y., Kozawa, E. ... Nishida, Y. (2014). Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients. Oncology Letters, 8, 2485-2488. https://doi.org/10.3892/ol.2014.2567
MLA
Urakawa, H., Tsukushi, S., Sugiura, H., Yamada, K., Yamada, Y., Kozawa, E., Arai, E., Futamura, N., Ishiguro, N., Nishida, Y."Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients". Oncology Letters 8.6 (2014): 2485-2488.
Chicago
Urakawa, H., Tsukushi, S., Sugiura, H., Yamada, K., Yamada, Y., Kozawa, E., Arai, E., Futamura, N., Ishiguro, N., Nishida, Y."Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients". Oncology Letters 8, no. 6 (2014): 2485-2488. https://doi.org/10.3892/ol.2014.2567